Skip to main content
SpringerLink
Log in

The National Institute for Health and Clinical Excellence (NICE) and Drug Treatment for Alzheimer’s Disease

  • Current Opinion
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Britain’s National Institute for Health and Clinical Excellence (NICE) has recently issued guidance that restricts the use of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s disease in the National Health Service. This stance contains lessons for designers of trials, drug regulators, health economists and those developing clinical guidelines for dementia care. The debates that took place around and within NICE were about identifying the benefits of these medicines and the beneficiaries, clarifying the costs of the medication and whom bears them, the methods of weighing benefit against cost, and the consequences of using different approaches to cost-benefit analysis. This article discusses each of these themes and outlines the changes in research and clinical practice and policy making that might flow from NICE’S decisions on medication use. Outcome measures that capture changes in dementia syndromes need further development. Cost-benefit analysis needs refinement with better tools than quality-adjusted life-years, and the policy implications of restricting treatments in a progressive neurodegenerative disorder need more careful consideration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maidment I, Fox C, Livingston G, et al. Drug treatment for Alzheimer’s disease: the way forward. Int J Geriatr Psychiatry 2006; 21: 6–8

    Article  PubMed  Google Scholar 

  2. Schneider L. The post-modern world of Alzheimer’s disease trials: how much is an ADAS-cog point worth in central London? Int J Geriatr Psychiatry 2006; 21: 9–13

    Article  PubMed  Google Scholar 

  3. National Institute for Health and Clinical Excellence. Dementia: clinical guideline [online]. Available from URL: http://www.nice.org.uk/guidance/cg42 [Accessed 2007 Jan 16]

  4. Winblad B, Engedal K, Soininen H, et al. A 1 year randomised placebo-controlled study in patients with mild-to-moderate AD. Neurology 2001; 57: 489–95

    Article  PubMed  CAS  Google Scholar 

  5. Mohs R, Doody R, Morris J, et al. A 1 year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–8

    Article  PubMed  CAS  Google Scholar 

  6. Raskind M, Peskingd E, Wessel T, et al. Galantamine in AD: a 6 month randomised placebo-controlled trial with a 6 month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8

    CAS  Google Scholar 

  7. Schneider L, Anand R, Farlow M. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65

    Google Scholar 

  8. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. New Engl J Med 2003; 348: 1333–41

    Article  PubMed  CAS  Google Scholar 

  9. National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk [Accessed 2007 Jan 16]

  10. Gureje O, Oguyinni A, Kola L. The profile and impact of probable dementia in a sub-Saharan African community: results from the Ibadan Study of Aging. J Psychosom Res 2006; 61: 327–33

    Article  PubMed  Google Scholar 

  11. Rockwood K. The measuring, meaning and importance of ADL as an outcome. Presentation to the International Psychiatric Association Consensus Conference; 2006 Oct 31–Nov 1; Canterbury

  12. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 677–85

    Article  PubMed  CAS  Google Scholar 

  13. Chiu H, Zhang H. Dementia research in China. Int J Geriatric Psychiatry 2000; 15: 947–53

    Article  CAS  Google Scholar 

  14. Rabins PV. Measuring quality of life in dementia: purposes, goals, challenges and progress. Presentation to the International Psychiatric Association Consensus Conference; 2006 Oct 31–Nov 1; Canterbury

  15. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11Suppl. 3: 8–18

    PubMed  Google Scholar 

  16. Brodaty H. Meaning and measurement of caregiver outcomes. Presentation to the International Psychiatric Association Consensus Conference; 2006 Oct 31–Nov 1; Canterbury

  17. Brodaty H, Green A, Low LF. Family caregivers for people with dementia: carer burden and stress. In: Burns A, O’Brien J, Ames D, editors. Dementia. London: Hodder Arnold, 2005

    Google Scholar 

  18. European Commission. EUROSTAT 2001 data [online]. Available from URL: http://www.europa.eu.int/comm/eurostat/Public/datashop/print-product/EN?.catalogue=eurostat &product=3–20theme3-EN&mode = = download Table 12, Theme 3, Population and Social conditions: Key Indicators Collection: Indicators by Theme; release 1.61. [Accessed 2006 Nov 1]

  19. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54(11 Suppl. 5): S4–9

    PubMed  CAS  Google Scholar 

  20. Gray A, Fenn P. Alzheimer’s disease: the burden of the illness in England. Health Trends 1993; 25: 31–7

    PubMed  CAS  Google Scholar 

  21. Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry 1997; 12: 841–56

    Article  PubMed  CAS  Google Scholar 

  22. Bosanquet N, May J, Johnson N. Alzheimer’s disease in the United Kingdom: burden of disease and future care. London: Imperial College, 1998

    Google Scholar 

  23. Evans R, McGrail K, Morgan S, et al. Apocalypse no: population aging and the future of health care systems. Can J Aging 2001; 20Suppl. 1: 160–91

    Article  Google Scholar 

  24. Smith SC, Lamping DL, Banerjee S, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005; 9(10): 1–93

    CAS  Google Scholar 

  25. Rawlins M, Culyer A. NICE and its value judgements. BMJ 2004; 239: 224–7

    Article  Google Scholar 

  26. The Royal College of Psychiatrists. Appeal from the Royal College of Psychiatrists and the British Geriatrics Society regarding the NICE Final Appraisal Document: donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease [online]. Available from URL: http://www.rcpsych.ac.uk/PDF/AlzletterNice0606.pdf [Accessed 2007 Jan 16]

  27. Wimo A, Winblad B. Pharmacoeconomic outcomes. In: Rock-wood K, Gauthier S, editors. Trial designs and outcomes in dementia therapeutic research. Abingdon: Taylor & Francis, 2006: 250–8

    Google Scholar 

  28. Boyer F, Novella JL, Morrone I, et al. Agreement between dementia patient report and proxy reports using the Nottingham Health Profile. Int J Geriatric Psychiatry 2004; 19: 1026–34

    Article  CAS  Google Scholar 

  29. Coucill W, Bryan S, Bentham P, et al. EQ-5D in patients with dementia: an investigation of inter-rater agreement. Med Care 2001; 39: 760–71

    Article  PubMed  CAS  Google Scholar 

  30. Iliffe S, Manthorpe J. Drugs: consider the probable side effects. J Dementia Care 2005; 13(2): 33–5

    Google Scholar 

Download references

Acknowledgements

The author was a member of the NICE/SCIE Dementia Guidelines Development Group 2004–6, and in the past has received unrestricted research funding from Eisai/Pfizer. No sources of funding were used in the preparation of this review.

Author information

Authors and Affiliations

  1. University College London, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, England

    Steve Iliffe

Authors
  1. Steve Iliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steve Iliffe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iliffe, S. The National Institute for Health and Clinical Excellence (NICE) and Drug Treatment for Alzheimer’s Disease. CNS Drugs 21, 177–184 (2007). https://doi.org/10.2165/00023210-200721030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721030-00001

Keywords

Search

Navigation